330
Participants
Start Date
July 31, 2014
Primary Completion Date
February 28, 2022
Study Completion Date
February 28, 2022
autologous EBV specific Cytotoxic T cells
The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
combination IV gemcitabine and IV carboplatin (AUC2)
4 cycles for Arm A and 6 cycles for Arm B
Baylor Scott & White, Dallas
Baylor College of Medicine, Houston
City of Hope National Medical Center, Duarte
UCSF HDF Comprehensive Cancer Center, San Francisco
Stanford Cancer Center, Stanford
University of California Davis Health, Sacramento
Massachusetts General Hospital, Boston
Site MY-03, George Town
Site MY-06, George Town
Site MY-07, Johor Bahru
Site MY-01, Kuala Lumpur
Site MY-04, Kuala Lumpur
Site MY-05, Kuala Lumpur
Site MY-08, Kuala Lumpur
Site SG-11, Singapore
Site SG-12, Singapore
Changhua Christian Hospital, Changhua
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
China Medical University Hospital, Taichung
Taichung Veterans General Hospital, Taichung
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Linkou Chang Gung Memorial Hospital, Taoyuan District
Site TH-42, Bangkok
Site TH-43, Bangkok
Site TH-41, Chiang Mai
Site TH-44, Khon Kaen
Site TH-47, Lopburi
Site TH-45, Ubon Ratchathani
Site TH-46, Udon Thani
Lead Sponsor
Tessa Therapeutics
INDUSTRY